The effects of inspiratory muscle training on plasma interleukin-6 concentration during cycling exercise and a volitional mimic of the exercise hyperpnea

Dean E. Mills,1 Michael A. Johnson,1 Martin J. McPhilimey,1 Neil C. Williams,1 Javier T. Gonzalez,2 Yvonne A. Barnett,1 and Graham R. Sharpe1

1Sport, Health and Performance Enhancement (SHAPE) Research Group, School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom; and 2School of Life Sciences, Northumbria University, Newcastle upon Tyne, United Kingdom

Submitted 1 March 2013; accepted in final form 24 July 2013

Mills DE, Johnson MA, McPhilimey MJ, Williams NC, Gonzalez JT, Barnett YA, Sharpe GR. The effects of inspiratory muscle training on plasma interleukin-6 concentration during cycling exercise and a volitional mimic of the exercise hyperpnea. J Appl Physiol 115: 1163–1172, 2013. First published July 25, 2013; doi:10.1152/japplphysiol.00272.2013.—It is unknown whether the respiratory muscles contribute to exercise-induced increases in plasma interleukin-6 (IL-6) concentration, if this is related to diaphragm fatigue, and whether inspiratory muscle training (IMT) attenuates the plasma IL-6 response to whole body exercise and/or a volitional mimic of the exercise hyperpnea. Twelve healthy males were divided equally into an IMT or placebo (PLA) group, and before and after a 6-wk intervention they undertook, on separate days, 1 h of 1) passive rest, 2) cycling exercise at estimated maximal lactate steady state power (EX), and 3) volitional hyperpnea at rest, which mimicked the breathing and respiratory muscle recruitment patterns achieved during EX (HYPEX). Plasma IL-6 concentration remained unchanged during passive rest. The plasma IL-6 response to EX was reduced following IMT (main effect of intervention, \(P = 0.039\)) but not PLA (\(P = 0.272\)). Plasma IL-6 concentration increased during HYPEX (main effect of time, \(P < 0.01\)) and was unchanged postintervention. There was no evidence of diaphragm fatigue (measured by phrenic nerve stimulation) following each trial. In conclusion, plasma IL-6 concentration is increased during EX and HYPEX and this occurred in the absence of diaphragm fatigue. Furthermore, IMT reduced the plasma IL-6 response to EX but not HYPEX. These findings suggest that the respiratory muscles contribute to exercise-induced increases in plasma IL-6 concentration in the absence of diaphragm fatigue and that IMT can reduce the magnitude of the response to exercise but not a volitional mimic of the exercise hyperpnea.

interleukin-6; exercise; respiratory muscles; diaphragm fatigue; inspiratory muscle training

INCREASED RESPIRATORY MUSCLE work is encountered during strenuous whole body exercise, asthma attacks, and exacerbations of chronic obstructive pulmonary disease (COPD) and when sufficiently strenuous can result in diaphragmatic fatigue. These scenarios can result in systemic inflammation and oxidative stress due to enhanced production of inflammatory cytokines and reactive oxygen species (ROS), respectively (35, 50, 68).

During whole body exercise the myokine interleukin-6 (IL-6) demonstrates the largest increase (50), with contracting skeletal muscle accounting for most (but not all) of the exercise-induced increase in plasma IL-6 concentration (58). IL-6 acts to stimulate lipolysis (67), hepatic glucose output (20), and glucose uptake in the contracting myocytes (10). However, not all skeletal muscles release the same amount of IL-6 during whole body exercise. When expressed relative to the size of the muscle group used, the arm muscles release greater amounts of IL-6 than leg muscles, which may be due to differences in fiber-type composition and vascular supply (26).

The respiratory muscles also exhibit different fiber-type composition and vascular supply compared with leg muscles (48), but given their relatively small mass (~960 g [23]) it may seem unlikely that they contribute to exercise-induced increases in plasma IL-6 concentration. However, Vassilakopoulos et al. (64) reported a 120% increase in plasma IL-6 concentration in young and healthy humans following inspiratory resistive loading (IRL) at 75% maximal inspiratory mouth pressure (MIP). The increase in plasma IL-6 concentration was attributed to increased rates of IL-6 release from the inspiratory muscles, which is supported by the observation of increased IL-6 mRNA and protein expression in the diaphragm of rats exposed to IRL (53, 54, 62). Although these findings have clinical relevance to those with asthma and obstructive lung disease, they cannot be generalized to healthy humans performing whole body exercise as, compared with IRL, spontaneous exercise hyperpnea elicits different breathing and respiratory muscle recruitment patterns (14, 15, 18).

Vassilakopoulos et al. (63, 64) also suggested that the increase in plasma IL-6 concentration (and other cytokines) may be due to inspiratory/diaphragm muscle fiber injury/fatigue since IRL was performed until task failure, which occurred after 54 ± 10 min. However, inspiratory muscle fatigue was assessed using a volitional measure of MIP, which may decline following IRL until task failure due to a decrease in central drive globally rather than diaphragm fatigue (2, 44). The question of whether respiratory muscles release IL-6 during exercise and if this is related to diaphragm fatigue may be better addressed using volitional hyperpnea at rest. In this model, validity is improved by mimicking the breathing and respiratory muscle recruitment patterns experienced during whole body exercise (4, 36). The presence of diaphragm fatigue can also be measured more objectively by using bilateral phrenic nerve stimulation (2).

Recent evidence suggests that the plasma IL-6 response to exercise is attenuated following whole body resistance (30) and endurance (1, 16, 70) training. Increases in basal levels of IL-6
METHODS

Participants. Twelve nonsmoking recreationally active males provided written, informed consent to participate in the study, which was approved by the local ethics committee. A self-reporting medical questionnaire confirmed that participants were free from illness and injury and not taking any medication and/or antioxidant supplements during the study. Each participant completed a 24-h diet record prior to their first trial, which was then replicated prior to all subsequent trials. Throughout the study, participants were instructed to adhere to their habitual training regimen and not to engage in any strenuous exercise the day preceding and the day of a trial. Participants arrived at the laboratory 4 h postprandially, having abstained from alcohol and caffeine in the 24 h before testing.

Experimental design. Participants attended the laboratory on six separate occasions, before and after a 6-wk intervention (Fig. 1). Each laboratory visit was separated by 48 h and took place at the same time of day. During the first visit, participants were familiarized with all testing procedures and pulmonary function and MIP were measured. During the second visit participants performed a cycling lactate minimum test to estimate maximal lactate steady state power. The subsequent three experimental trials lasted 1 h and comprised 1) passive rest (PASSIVE), 2) cycling exercise at the participants lactate minimum power (EX), and 3) volitional hyperpnea at rest whereby participants mimicked the breathing and respiratory muscle recruitment patterns achieved during EX (HYPEX). Since EX had to precede HYPEX, the experimental trials were only partially randomized. Following the final trial, participants were randomly, and equally, divided into an IMT or placebo (PLA) group and completed the intervention. At least 48 h postintervention, participants repeated the lactate minimum test and experimental trials in the same order as preintervention. All trials were performed on an electromagnetically braked cycle ergometer (Excalibur Sport; Lode, Groningen, Netherlands).

Pulmonary function and maximal inspiratory mouth pressure. Pulmonary function was assessed according to published guidelines (46) using a pneumotachograph (Pneumotrac; Vitalograph, Buckinghamshire, UK) calibrated with a 3-liter syringe. A hand-held mouth pressure meter (MicroRPM; CareFusion, Hampshire, UK) measured MIP as an index of global inspiratory muscle strength. The mouth-piece assembly incorporated a 1 mm orifice to prevent glottic closure during inspiratory efforts. Maneuvers were performed while standing, initiated from residual volume, and sustained for at least 1 s. Repeat efforts separated by 30 s were performed until three serial measures differed by no more than 10% or 10 cmH2O, whichever was smallest (7, 8, 31). The highest value recorded was used for subsequent analysis.

Lactate minimum test. The lactate minimum test was performed following the procedures of Johnson et al. (32) who reported excellent agreement between lactate minimum and maximal lactate steady-state cycling powers (mean bias ± 95% limits of agreement: 2 ± 22 W). The test comprised three consecutive phases: 1) blood lactate concentration ([La−]B) elevation phase comprising maximal incremental exercise, 2) 8 min recovery phase at 60 W, and 3) incremental phase comprising five consecutive 4-min exercise stages at intensities of 45, 50, 55, 60, and 65% of the maximum power achieved during the lactate elevation phase. During the [La−]B elevation phase, power output was increased by 10 W every 15 s to elicit exercise intolerance in ~10 min. The highest oxygen uptake recorded in any 30 s period defined peak oxygen uptake (V̇O2peak). During the incremental phase, blood samples were taken in the final seconds of each stage, and the lactate minimum power (i.e., estimated maximal lactate steady state power) was calculated as the nadir of a second-order polynomial fitting the [La−]B against power data.

Experimental trials. During experimental trials the configuration of the cycle ergometer and the body position adopted by each participant were identical to those adopted during the lactate minimum test. Each trial was preceded by a 5-min rest period, and during PASSIVE participants remained seated on the cycle ergometer for the duration...
of the trial. During pre- and postintervention EX trials participants cycled at their preintervention calculated maximum power and each participant adopted the same cycling cadence during all trials. During HYPEX participants mimicked the breathing (tidal volume, VT; breathing frequency, fT; and duty cycle, Td/TTOT) and respiratory muscle recruitment (peak transdiaphragmatic pressure, Pdipeak) patterns attained during preintervention EX. These variables were ensemble averaged into six 10-min blocks from the EX data and targets were updated during the HYPEX trial. During the postintervention HYPEX trial, participants mimicked the breathing and respiratory muscle recruitment patterns performed during the preintervention HYPEX trial. An audio metronome paced fT and Td/TTOT, and real-time visual feedback of VT and Pdipeak was provided throughout.

The use of Pdipeak targets allowed us to more precisely control the mechanical work of breathing during volitional hyperpnea (4, 36). All experimental trials were performed in an environmental chamber (Design Environmental WIR52–20HS; Design Environmental, Gwent, UK) at 20°C and 90% relative humidity to minimize mucosal drying during trials. Participants initially rested for 20 min to minimize postactivation recovery of the diaphragm (59). Both pre- and postintervention EX trials were preceded by a 20-min warm-up and participants were seated upright with no abdominal binding (37, 42), wore a noseclip, and prior to stimulation were instructed to hold at functional residual capacity (28, 55), which was confirmed from visual feedback of FRC.

Skin surface electromyography (EMG) of the right costal diaphragm was recorded using bipolar surface electrodes (self-adhesive, Ag–AgCl, 10 mm recording surface diameter; Unilect, Worcestershire, UK) placed on the sixth and eighth intercostal spaces in the anterior axillary line (24). Electrodes were positioned to optimize peak to peak amplitude of M-wave responses. EMG signals were passed through a differential amplifier (1902 Mk IV; Cambridge Electronic Design, Cambridge, UK), sampled at 2,000 Hz using an analog-digital converter (Micro 1401; Cambridge Electronic Design) and recorded using specific data acquisition software (Spike 2 version 5.12; Cambridge Electronic Design).

To determine supramaximal phrenic nerve stimulation, three single switches were obtained every 30 s at intensities of 50, 60, 70, 80, 85, 90, 95, and 100% of maximal stimulator output. A plateau in Pdive and M-wave responses with increasing stimulation intensities indicated maximum depolarization of the phrenic nerves. The technical considerations regarding supramaximal stimulation have been described previously (17, 59). Pdive was assessed every 30 s using eight single stimuli at 100% of maximal stimulator output. Pdive was measured at baseline and within 15 (<15 min), 35 (<35 min), and 60 (<60 min) min after each experimental trial. Additionally, Pdive at each measurement point was followed by the assessment of the potentiated Pdive response. Participants performed a 3-s maximal Müllner maneuver and ~5 s later a single stimulus was delivered. This procedure was repeated six times with each measure separated by 30 s. A potentiated Pdive has greater sensitivity to fatigue especially when the degree of fatigue is small (39, 40). The average of the median three individual Pdive responses were used for analysis. Diaphragm fatigue was defined as a >15% reduction in Pdive compared with the baseline value (38).

Blood analyses and additional measurements. Arterialized venous blood was sampled from a dorsal hand vein via an indwelling 21-G cannula (45). Arterialization was ensured by immersing the hand in water at 40°C for 10 min prior to cannulation and by warming the hand during trials using an infrared lamp. During the experimental trials blood samples were taken at rest, every 3 min for the initial 15 min, and every 5 min thereafter, and analyzed immediately for PCO2 and pH (ABL520; Radiometer, Copenhagen, Denmark), which were measured in duplicate using a commercial solid phase sandwich ELISA (Quantikine HS; R&D Systems, Abingdon, UK). The assay has a detection limit of 0.039 pg/ml. To minimize the effect of hand ischemia and leg discomfort using Borg’s modified CR10 scale (6). At rest, immediately after (0 h) and 1 (+1 h), 2 (+2 h), and 24 (+24 h) h after each experimental trial, 5 ml blood samples were taken for the measurement of plasma IL-6 concentration. Blood was transferred into precooled tubes containing 1.6 mg/ml of K2-E EDTA (SARSTEDT, Leicester, UK) and immediately centrifuged for 15 min at 1,000 × g and 5°C. The plasma supernatant was subsequently removed and stored at −80°C until further analysis. Plasma IL-6 concentrations were measured in duplicate using a commercial solid phase sandwich ELISA (Quantikine HS; R&D Systems, Abingdon, UK). The assay has a detection limit of 0.039 pg/ml.
assay coefficient of variation (CV) for plasma IL-6 concentration was <10%.

**Inspiratory muscle training and placebo interventions.** The intervention lasted 6 wk. The IMT group performed 30 consecutive dynamic inspiratory efforts twice daily using an inspiratory pressure-threshold device (POWERbreathe Classic series 1st generation; Gaia, UK). The initial training load was 50% MIP. Thereafter, participants periodically increased the load so that 30 maneuvers could only just be completed. Each inspiratory effort was initiated from residual volume and participants strove to maximize Vt. This regimen is known to be effective in eliciting an adaptive response (7–9, 52). The PLA group inhaled one puff twice daily from a sham metered dose inhaler (Vitalograph). The inhaler contained compressed air only but was promoted to the participants as delivering a novel drug that reduces breathing-induced inflammation. During the postintervention period the IMT and PLA groups performed their intervention 2 days/wk, which is sufficient to maintain improvements in inspiratory muscle function following IMT (52). These maintenance sessions were performed 48 h before and 48 h after experimental trials. All participants completed a training diary throughout the study to record adherence to the prescribed intervention and whole body training sessions.

**Statistical analyses.** Statistical analyses were performed using SPSS for Windows (IBM, Chicago, IL). Between- and within-group comparisons of baselines characteristics, including pulmonary function and MIP, were made using independent and paired t-tests, respectively. A three-way ANOVA was used to analyze the effects of “intervention” (pre- vs. post-“treatment”) and “time” (10, 20, 30, 40, 50, and 60 min for all physiological and perceptual variables; 0, +1, +2, and +24 h for plasma IL-6 data; or baseline, <15, <35, and <60 min for \( P_{aw} \) data) with a between-subject factor of “trial” (EX vs. HYPEX) for breathing and respiratory muscle recruitment pattern data, or “treatment” (IMT vs. PLA) for all other data. Intervention × treatment interaction effects and within-group changes were further explored by analyzing IMT and PLA groups separately using two-way repeated measures ANOVA. Reliability was assessed using a CV calculated from a pooled mean of both groups and all trials. Statistical significance was set at \( P < 0.05 \). Results are presented as means ± SD.

**RESULTS**

Age (IMT vs. PLA: 27 ± 7 vs. 22 ± 3 yr), body mass (80 ± 6 vs. 74 ± 7 kg), height (181 ± 5 vs. 177 ± 4 cm), and \( V_{O2peak} \) (52 ± 6.2 vs. 47 ± 5.7 ml·kg\(^{-1}\)·min\(^{-1}\)) were not different between groups. Maximum power (378 ± 22 vs. 336 ± 23 W) and lactate minimum power (199 ± 8 vs. 170 ± 19 W) were higher \((P < 0.01)\) in the IMT group compared with the PLA group. All other preintervention measurements were not different between groups. \( V_{O2peak} \), maximum power, and lactate minimum power were unchanged after both IMT and PLA. In both groups all responses remained unchanged throughout PASSIVE trials (data not shown).

**Pulmonary function and maximal inspiratory pressure.** Preintervention pulmonary function (data not shown) and MIP were within normal limits. Compliance with the intervention was excellent in both IMT and PLA groups with 96 ± 1 and 93 ± 1% of sessions completed, respectively. Pulmonary function was unchanged in both groups postintervention, whereas MIP increased from 168 ± 49 to 202 ± 39 cmH\(_2\)O (+24 ± 16%) after IMT \((P < 0.01)\). Inspection of training diaries revealed habitual whole-body training remained constant in both groups.

**Breathing and respiratory muscle recruitment patterns.** When performed separately for IMT and PLA groups, three-way ANOVA with repeated measures across intervention (pre- vs. posttreatment) and time (10, 20, 30, 40, 50, and 60 min), with a between-subject factor of trial (EX vs. HYPEX), revealed no main effects of intervention or trial for breathing and

### Table 1. Physiological and perceptual responses to EX and HYPEX trials for IMT and PLA groups

<table>
<thead>
<tr>
<th></th>
<th>EX</th>
<th>HYPEX</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Preintervention</td>
<td>Postintervention</td>
</tr>
<tr>
<td></td>
<td>Preintervention</td>
<td>Postintervention</td>
</tr>
<tr>
<td><strong>IMT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( V_{E} ), l/min</td>
<td>81.0 ± 13.0</td>
<td>75.1 ± 6.1</td>
</tr>
<tr>
<td>( V_{T} ), liters</td>
<td>2.41 ± 0.53</td>
<td>2.40 ± 0.53</td>
</tr>
<tr>
<td>( f_{b} ), breaths/min</td>
<td>36 ± 9</td>
<td>33 ± 6</td>
</tr>
<tr>
<td>( T_{I}/T_{TOT} )</td>
<td>0.47 ± 0.04</td>
<td>0.48 ± 0.02</td>
</tr>
<tr>
<td>( [\text{La}^-]_a ), mmol/l</td>
<td>4.21 ± 1.88</td>
<td>2.74 ± 1.08</td>
</tr>
<tr>
<td>( \text{pH} )</td>
<td>7.357 ± 0.031</td>
<td>7.376 ± 0.020</td>
</tr>
<tr>
<td>( P_{CO2} ), mmHg</td>
<td>41.8 ± 3.5</td>
<td>41.4 ± 3.1</td>
</tr>
<tr>
<td>( f_c ), beats/min</td>
<td>163 ± 15</td>
<td>159 ± 14</td>
</tr>
<tr>
<td>( SpO_2 ), %</td>
<td>95 ± 1</td>
<td>95 ± 1</td>
</tr>
<tr>
<td>RPE (dyspnea)</td>
<td>3.9 ± 1.7</td>
<td>2.0 ± 1.5</td>
</tr>
<tr>
<td>RPE (leg)</td>
<td>5.8 ± 1.3</td>
<td>5.2 ± 1.2</td>
</tr>
<tr>
<td><strong>PLA</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( V_{E} ), l/min</td>
<td>61.6 ± 14.5</td>
<td>59.6 ± 12.5</td>
</tr>
<tr>
<td>( V_{T} ), liters</td>
<td>1.77 ± 0.34</td>
<td>1.78 ± 0.27</td>
</tr>
<tr>
<td>( f_{b} ), breaths/min</td>
<td>36 ± 7</td>
<td>35 ± 7</td>
</tr>
<tr>
<td>( T_{I}/T_{TOT} )</td>
<td>0.48 ± 0.01</td>
<td>0.48 ± 0.02</td>
</tr>
<tr>
<td>( [\text{La}^-]_a ), mmol/l</td>
<td>4.20 ± 1.19</td>
<td>4.00 ± 1.13</td>
</tr>
<tr>
<td>( \text{pH} )</td>
<td>7.358 ± 0.017</td>
<td>7.395 ± 0.022</td>
</tr>
<tr>
<td>( P_{CO2} ), mmHg</td>
<td>41.2 ± 2.7</td>
<td>41.1 ± 2.6</td>
</tr>
<tr>
<td>( f_c ), beats/min</td>
<td>158 ± 16</td>
<td>153 ± 14</td>
</tr>
<tr>
<td>( SpO_2 ), %</td>
<td>96 ± 1</td>
<td>96 ± 1</td>
</tr>
<tr>
<td>RPE (dyspnea)</td>
<td>3.7 ± 2.9</td>
<td>3.2 ± 4.4</td>
</tr>
<tr>
<td>RPE (leg)</td>
<td>5.1 ± 2.7</td>
<td>5.2 ± 3.4</td>
</tr>
</tbody>
</table>

Values are mean ± SD. \( V_{E} \), minute ventilation; \( V_{T} \), tidal volume; \( f_{b} \), breathing frequency; \( T_{I}/T_{TOT} \), duty cycle; \( [\text{La}^-]_a \), blood lactate concentration; \( P_{CO2} \), partial pressure of carbon dioxide; \( f_c \), cardiac frequency; \( SpO_2 \), arterial oxygen saturation; RPE, rating of perceived exertion. See text for description of analyses.

_j Appl Physiol_ • doi:10.1152/japplphysiol.00272.2013 • www.jappl.org
respiratory muscle recruitment patterns. This shows that the breathing and respiratory muscle recruitment patterns observed during EX were successfully mimicked in HYPEX and that these factors were the same before and after IMT and PLA (Table 1 and Figs. 2 and 3). The only exception was that in the IMT group PTP di/PTPe changed differently over time between the two trials (trial × time interaction, \(P = 0.008\)) and in the PLA group PTP di changed differently over time between the two trials (trial × time interaction, \(P = 0.026\)) (Table 1 and Figs. 2 and 3). The intertrial CV for \(P_{dipeak}\) at rest was <7%.

**Plasma interleukin-6 concentration.** For EX trial plasma IL-6 concentration data, three-way ANOVA with repeated measures across intervention (pre- vs. posttreatment) and time (0, +1, +2, and +24 h), with a between-subject factor of treatment (IMT vs. PLA), revealed a main effect of time (\(P < 0.01\)) and intervention (\(P = 0.013\)) and a trend for an interaction (\(P = 0.093\)) (Fig. 4). To explore the nature of this interaction subsequent, two-way ANOVA with repeated measures across time (0, +1, +2, and +24 h) and intervention (pre- vs. posttreatment) were performed separately for IMT and PLA groups and revealed that plasma IL-6 concentration was reduced after IMT (main effect of intervention, \(P = 0.039\)), whereas there was no change after PLA (\(P = 0.272\)). For HYPEX trial plasma IL-6 concentration data, three-way ANOVA revealed a main effect of time (\(P <
but not for intervention (P = 0.306), and no intervention \times treatment interaction (P = 0.304) (Fig. 4).

Blood lactate concentration, pH, and PCO$_2$. For EX trial data, three-way ANOVA with repeated measures across intervention (pre- vs. posttreatment) and time (10, 20, 30, 40, 50, and 60 min), with a between-subject factor of treatment (PLA vs. IMT), revealed intervention \times treatment interactions for [La$^{-}$]$_B$ (P = 0.016) and pH (P = 0.050) (Table 1). To explore the nature of these interactions, subsequent two-way ANOVA with repeated measures across time (10, 20, 30, 40, 50, and 60 min) and intervention (pre- vs. posttreatment) were performed separately for IMT and PLA groups. After IMT, [La$^{-}$]$_B$ was reduced and pH was higher (main effects of intervention, P < 0.01), whereas [La$^{-}$]$_B$ and pH were unchanged after PLA. PCO$_2$ during EX was unchanged postintervention (Table 1). During the preintervention HYPEX trial resting [La$^{-}$]$_B$ was 0.57 ± 0.11 and 0.76 ± 0.12 mmol/l in IMT and PLA groups, respectively. A three-way ANOVA revealed that [La$^{-}$]$_B$ increased (main effect of time, P = 0.042) and responses were unchanged postintervention (Table 1). There was no main effect of time for pH and PCO$_2$ showing that these variables were maintained at rest during HYPEX (Table 1).

Twitch transdiaphragmatic pressures. A plateau (i.e., no significant increase in amplitude with increasing stimulation intensity) in P$_{dive}$ and M-wave amplitude (data not shown) was observed in response to supramaximal BAMPS, indicating
maximal depolarization of the phrenic nerves. Preintervention $P_{\text{dsw}}$ and potentiated $P_{\text{dsw}}$ for the IMT group were $15.6 \pm 5.1$ and $23.3 \pm 8.6$ cmH$_2$O at baseline during EX and the inter- and intratrial CV for baseline $P_{\text{dsw}}$ and potentiated $P_{\text{dsw}}$ was <8%. Three-way ANOVA with repeated measures across intervention (pre- vs. posttreatment) and time (baseline, <15, <35, and <60 min), with a between-subject factor of treatment (PLA vs. IMT), revealed no main or interaction effects for $P_{\text{dsw}}$ and potentiated $P_{\text{dsw}}$ in either EX or HYPEX. Therefore there was no evidence of diaphragm fatigue following any trial.

Perceptual responses, cardiac frequency, and arterial oxygen saturation. For EX trial data, three-way ANOVA with repeated measures across intervention (pre- vs. posttreatment) and time (10, 20, 30, 40, 50, and 60 min), with a between-subject factor of treatment (PLA vs. IMT), revealed a main effect of intervention ($P = 0.010$) and an intervention × time × treatment interaction ($P = 0.012$) for RPE (dyspnea) (Table 1). To explore the nature of these findings, subsequent two-way ANOVA with repeated measures across intervention (pre- vs. posttreatment) and time (10, 20, 30, 40, 50, and 60 min) and intervention (pre- vs. posttreatment) were performed separately for IMT and PLA groups. RPE (dyspnea) was lower after IMT (main effects of intervention, $P = 0.006$) but unchanged after PLA. For HYPEX trial data, three-way ANOVA revealed an intervention × treatment interaction ($P = 0.024$) for RPE (dyspnea) (Table 1). To explore the nature of this interaction, subsequent two-way ANOVA performed separately for IMT and PLA groups revealed a trend for RPE (dyspnea) to be lower after IMT (main effect of intervention, $P = 0.054$) but not after PLA. Three-way ANOVA revealed no main or interaction effects for RPE (leg), $f_c$, or SpO$_2$ in EX or HYPEX trials (Table 1).

DISCUSSION

Main findings. The main findings of this study were that plasma IL-6 concentration increased following strenuous whole-body exercise (EX) and a volitional mimic of the breathing and respiratory muscle recruitment patterns achieved during EX (HYPEX) and that these increases occurred in the absence of diaphragm fatigue. In addition, the plasma IL-6 response to EX was attenuated following IMT.

To our knowledge, we are the first to report an increase in plasma IL-6 concentration following a volitional mimic of the exercise hyperpnea. The increase in IL-6 following HYPEX was of a similar magnitude to that reported following IRL at 75% MIP until task failure (64). However, our experimental model provides a more ecologically valid approach to assess whether the respiratory muscles release IL-6 during whole-body exercise. We are also confident that the increase in plasma IL-6 concentration observed during HYPEX is not an artifact of the experimental conditions since plasma IL-6 concentration was unchanged during the PASSIVE trial. Our data therefore suggest that the respiratory muscles do indeed contribute to the increase in plasma IL-6 concentration during whole-body exercise.

Stimuli for interleukin-6. The stimuli responsible for the increase in plasma IL-6 concentration following HYPEX could not be established from the present study. We found no evidence of diaphragm fatigue following HYPEX, and confidence in our data is supported by the demonstration of supramaximal stimulation in $P_{\text{dsw}}$ and M-wave responses and excellent inter-/intratrial reliability in $P_{\text{dsw}}$. Therefore our data do not support the notion (63, 64) that diaphragm fatigue triggers IL-6 release.

Oxidative stress due to enhanced generation of ROS and nitrogen species is an important regulator of IL-6 production. ROS can upregulate IL-6 in the diaphragms of rats exposed to IRL (54) and antioxidants can attenuate the plasma IL-6 response to IRL in humans (63). ROS are also upregulated by respiratory acidosis (3); however, we were careful to maintain PCO$_2$ at resting levels. Upstream of ROS, nitric oxide production may be involved in the transcriptional signaling of IL-6 (57) and has been shown to regulate IL-6 production within the diaphragm of rats exposed to IRL (53). However, since muscle glycogen depletion during prolonged and strenuous lower-
body exercise is a strong stimulus for enhanced IL-6 production by skeletal muscle fibers (34, 56), a more likely mechanism for the production of IL-6 may be a reduction in respiratory muscle glycogen content. This notion is supported by the reduced diaphragm glycogen content of murines exposed to IRL (13) and whole-body exercise (25, 29).

Source of plasma interleukin-6. Contracting skeletal muscle accounts for most (but not all) of the increase in plasma IL-6 concentration observed during whole body exercise (58). Thus, although our experimental model did not allow the source(s) of the increased plasma IL-6 during HYPEX to be established, we attribute this increase to, primarily, increased IL-6 release from contracting respiratory muscles. This notion is consistent with the increased IL-6 mRNA and protein expression in the diaphragm of rats exposed to IRL (53, 54, 62), and the higher IL-6 protein expression in the external intercostals of COPD patients compared with healthy controls (12).

However, there may have been additional contributions from other sources to the increase in plasma IL-6 concentration during HYPEX. Excessive expiratory muscle contractions during HYPEX (as evidenced by a higher PTPd), which has been previously observed in humans mimicking the pressure/flow characteristics of exercise hyperpnea (36), may have resulted in greater IL-6 release from expiratory muscles. The brain was also shown to release small amounts of IL-6 (~60 pg/min) following 60 min of cycling exercise (49). Furthermore, IL-6 may be upregulated within the lungs and subsequently enter the systemic circulation from permeation of epithelial and endothelial barriers with increased transmural pressures (61). This has been observed in murines exposed to negative or positive pressure ventilated hyperventilation (65) or IRL (60). However, this causes profound overdistension of the lung, which is unlikely during spontaneous hyperpnea in humans due to self-regulation of end-inspiratory and/or end-expiratory lung volumes.

When expressed relative to the size of the muscle group used, the arm muscles release greater amounts of IL-6 than leg muscles, and this is not directly related to release or uptake of exogenous substrate or muscle glycogen utilization (26). It may be possible that the respiratory muscles also contribute differently to systemic IL-6 release than other skeletal muscles due to differences in fiber type composition and vascular supply (48).

Effects of inspiratory muscle training on plasma interleukin-6 concentration. The present study is the first to demonstrate an attenuated plasma IL-6 response to whole-body exercise following IMT. Reduced IL-6 production by inspiratory muscles following IMT may result from increases in basal levels of IL-6 receptor α (1, 34) or antioxidant enzymes (70) or a reduction in muscle glycogen utilization (16, 22) secondary to training-induced increases in mitochondrial density (27). However, the decrease in plasma IL-6 concentration during EX is unlikely to be explained by these changes alone as 1) plasma IL-6 concentration during HYPEX was not reduced and 2) the reduction in plasma IL-6 concentration during EX following IMT was greater than the increase observed during HYPEX. Thus alternate explanations may exist. First, when isolated diaphragmatic fibers are incubated with CO2 there is an increase in ROS (3). If ROS are a stimuli for IL-6 production, the increase in pH during EX (which did not occur in HYPEX) may have downregulated IL-6 production within the leg and/or respiratory muscles. Second, while supporting empirical evidence is not strong, respiratory muscle metaboreflex activation may be attenuated by IMT (66), thus promoting increased blood flow to the liver (21) and/or leg muscles (43). Increased blood flow to the liver may increase hepatosplanchnic uptake of IL-6 (21), whereas increased leg blood flow may result in less muscle glycogen utilization due to increased oxygen (5) and/or glucose (19) delivery.

Application to asthma and COPD. Asthma attacks and COPD exacerbations lead to systemic inflammation due to inflammatory cytokines. The local source of these cytokines is not, however, fully understood. Some suggest that cytokines spill out from the lungs into the systemic circulation, whereas others suggest that multiple organs contribute (35, 68). Consistent with previous studies (11, 63, 64), our data suggest that the respiratory muscles directly contribute to the systemic inflammation observed in these patients when the work of breathing is increased. Furthermore, based on the findings of the present study, it is attractive to speculate that IMT may reduce the plasma IL-6 response during a period of increased respiratory muscle work in asthma and COPD patients.

Conclusion. In conclusion, plasma IL-6 concentration was increased, in the absence of diaphragm fatigue, following strenuous whole-body exercise (EX) and a volitional mimic of the exercise hyperpnea (HYPEX). Furthermore, the plasma IL-6 response to EX was attenuated following IMT. That the respiratory muscles may contribute to the increase in plasma IL-6 during whole body exercise raises several key questions: what other inflammatory cytokines are released from respiratory muscles during exercise and what are the key regulators of this IL-6 release? Are other cytokines increased/decreased following IMT and does this create a pro- or antiinflammatory response during exercise or volitional hyperpnea? What is the effect of IMT on the systemic inflammation observed in asthma and COPD patients?

ACKNOWLEDGMENTS

We acknowledge Dr. Rebecca Hill for her statistical support.

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the author(s).

AUTHOR CONTRIBUTIONS


REFERENCES


